Actively Recruiting
Long-Term Follow-up Protocol
Led by Krystal Biotech, Inc. · Updated on 2021-06-08
50
Participants Needed
3
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least one dose of investigational product (IP).
CONDITIONS
Official Title
Long-Term Follow-up Protocol
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All adult and pediatric participants who received at least one gene therapy treatment in a previous Krystal Biotech, Inc. sponsored study, and have discontinued or completed the parent treatment protocol which does not have the long-term follow-up embedded
- Consent or assent must be obtained by participants and parental/legal representatives when applicable before any study data collection
- Participant is willing and able to follow the protocol requirements
You will not qualify if you...
- Participants enrolled in a non-Krystal Biotech, Inc. interventional gene therapy clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Mission Dermatology Center
Rancho Santa Margarita, California, United States, 92688
Actively Recruiting
2
Stanford University
Redwood City, California, United States, 94063
Actively Recruiting
3
Pediatric Skin Research
Coral Gables, Florida, United States, 33146
Actively Recruiting
Research Team
B
Brittani Agostini
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here